3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms

Leukocyte Differentials and the Left Shift

Circulating white blood cells (WBCs) include neutrophils, lymphocytes, monocytes, eosinophils, and basophils. The CBC differential reports absolute and relative counts; absolute counts matter more than percentages when total WBC is abnormal. Neutrophilia commonly accompanies bacterial infection, tissue necrosis, corticosteroids (demargination), and catecholamine stress. Lymphocytosis may reflect viral infection or chronic lymphocytic processes. Eosinophilia suggests allergic disease, parasites, or certain neoplasms (for example, Hodgkin lymphoma). Basophilia can appear in myeloproliferative neoplasms.

A left shift means an increased proportion of immature neutrophils—especially band forms, and sometimes earlier myeloid precursors—in the peripheral blood. It reflects accelerated marrow release under cytokine drive (G-CSF and inflammatory mediators). Left shift with toxic granulation and Döhle bodies supports reactive infection/inflammation. Circulating myeloblasts, by contrast, raise concern for acute leukemia or a leukoerythroblastic reaction and must be interpreted with clinical context and marrow findings.

---

Acute vs Chronic Leukemias: Mechanism Markers

Leukemias are neoplastic proliferations of hematopoietic cells. Acute leukemias are defined by accumulation of immature blasts that crowd out normal hematopoiesis → anemia, infection risk (functional neutropenia), and thrombocytopenia/bleeding. Chronic leukemias accumulate more differentiated cells and often present with high counts and organomegaly before frank marrow failure.

Acute Lymphoblastic Leukemia (ALL)

ALL is the most common childhood leukemia. Lymphoblasts replace marrow; patients present with fatigue, fever, bleeding, bone pain, and sometimes CNS or testicular involvement. Blasts are typically TdT positive (terminal deoxynucleotidyl transferase marks immature lymphoid cells). B-ALL often expresses B-lineage markers; a historical “CALLA” (CD10) association appears in many teaching resources for common B-ALL. T-ALL may present with a mediastinal mass in adolescents. Genetic drivers vary (for example, hyperdiploidy favorable in some pediatric contexts; BCR–ABL1–positive ALL is a high-risk molecular subset). Mechanism focus for CBSE: immature lymphoid blast proliferation + TdT as immaturity marker + marrow failure phenotype.

Acute Myeloid Leukemia (AML)

AML is a myeloid blast neoplasm more common in adults. Myeloid lineage may be supported by cytochemistry (MPO positivity) and markers. Auer rods—crystalline fused primary granules—are pathognomonic for myeloid differentiation when present and are a classic exam smear clue. Subtypes matter mechanistically: acute promyelocytic leukemia (APL) harbors t(15;17) creating a PML–RARA fusion that blocks differentiation at the promyelocyte stage. APL cells are rich in procoagulant granules and strongly associate with DIC. Differentiation therapy with all-trans retinoic acid (ATRA) conceptually relieves the RARA-mediated repression—pharmacology tied directly to the fusion mechanism.

Therapy-related AML and AML after myelodysplasia reflect cumulative genetic injury; prior alkylator or topoisomerase II inhibitor exposure are classic associations in path questions.

Chronic Myeloid Leukemia (CML)

CML is a myeloproliferative neoplasm driven by t(9;22)—the Philadelphia chromosome—producing BCR–ABL1, a constitutively active tyrosine kinase. Uncontrolled granulocytic proliferation yields very high WBC with left shift spanning myelocytes to neutrophils, basophilia, and often thrombocytosis; splenomegaly is common. The chronic phase can accelerate or blast-transform into acute leukemia. Mechanistically, BCR–ABL1 activates proliferative and anti-apoptotic pathways (RAS, STAT, PI3K). Tyrosine kinase inhibitors target this fusion kinase—high-yield link from molecular lesion to therapy concept.

Chronic Lymphocytic Leukemia (CLL)

CLL is a neoplasm of mature-appearing B lymphocytes, typically in older adults. Cells often coexpress CD5 and CD23 with dim surface immunoglobulin—an immunophenotype that distinguishes CLL from many other B-cell lymphomas (mantle cell is also CD5+ but usually CD23− and carries cyclin D1/t(11;14) biology). Smudge cells on smear are a classic artifact of fragile CLL lymphocytes. Lymphadenopathy, infection susceptibility from immune dysregulation, autoimmune hemolysis, and progression to more aggressive large-cell transformation are mechanism-linked complications. Small lymphocytic lymphoma (SLL) is essentially the same disease process dominated by nodal disease rather than blood lymphocytosis.

---

Hodgkin vs Non-Hodgkin Lymphoma Patterns

Lymphomas are solid tumors of lymphoid tissue, though many spill into blood/marrow. Teaching contrasts emphasize cellular composition and clinical tempo rather than inventing staging rules.

Classical Hodgkin lymphoma features rare malignant Reed–Sternberg (RS) cells (or variants) in a rich inflammatory background of lymphocytes, eosinophils, plasma cells, and fibrosis depending on subtype. RS cells in classical disease often express CD15 and CD30 and are typically negative for CD20/CD45 in textbook patterns. Cytokines from RS cells recruit the inflammatory milieu and can cause B symptoms (fever, night sweats, weight loss). Nodular sclerosis subtype with cervical/mediastinal nodes in young adults is a classic vignette pattern. EBV association appears in some subtypes.

Non-Hodgkin lymphomas (NHL) are a heterogeneous group of B- or T/NK-cell neoplasms. Unlike Hodgkin lymphoma’s sparse malignant cells, NHL usually shows sheets of clonal lymphoid cells. Aggressive lymphomas (for example, diffuse large B-cell lymphoma, Burkitt lymphoma) grow rapidly and may present with masses and systemic symptoms; indolent lymphomas (for example, follicular lymphoma) may wax and wane over years. Burkitt lymphoma’s MYC translocation (classically t(8;14) IGH–MYC) drives ultra-rapid proliferation with a “starry sky” histology from tingible-body macrophages. Follicular lymphoma’s t(14;18) BCL2–IGH overexpression inhibits apoptosis. Mantle cell lymphoma’s t(11;14) cyclin D1 overexpression dysregulates cell-cycle progression. These are mechanism anchors—not a substitute for formal clinical staging systems used at the bedside.

---

Multiple Myeloma: CRAB Mechanisms

Multiple myeloma is a neoplastic proliferation of plasma cells producing a monoclonal immunoglobulin (M protein) or light chains. Pathophysiology maps cleanly onto the CRAB features:

• Calcium (hypercalcemia): Tumor-derived cytokines (RANKL, MIP-1α, others) activate osteoclasts and suppress osteoblasts → lytic bone lesions and calcium release.
• Renal failure: Light chains cast nephropathy, hypercalcemia, dehydration, and light-chain toxicity injure tubules; amyloid can contribute in some patients.
• Anemia: Marrow replacement by plasma cells plus cytokine suppression of erythropoiesis.
• Bone lesions: Purely lytic punched-out lesions from unopposed osteoclast activity; pathologic fractures and bone pain follow.

Additional mechanisms: rouleaux formation from high serum protein; elevated ESR; increased infection risk from functional hypogammaglobulinemia of normal plasma-cell clones; AL amyloidosis risk from light chains. Waldenström macroglobulinemia (lymphoplasmacytic lymphoma with IgM) is a related but distinct concept featuring hyperviscosity more than lytic CRAB bone disease.

---

Polycythemia Vera and Myeloproliferative Concepts

Myeloproliferative neoplasms (MPNs) are clonal disorders of multipotent hematopoietic progenitors with effective overproduction of one or more mature lineages. Classic BCR–ABL1–negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

Polycythemia vera is driven in nearly all cases by gain-of-function JAK2 mutations (most often V617F in the pseudokinase domain, less often exon 12 mutations). Constitutive JAK–STAT signaling makes erythroid progenitors EPO-independent or hypersensitive → elevated red-cell mass, often with leukocytosis/thrombocytosis, aquagenic pruritus, erythromelalgia, and thrombosis risk (including unusual sites such as hepatic vein thrombosis). Low EPO helps distinguish primary PV from secondary polycythemia (hypoxia, high-affinity hemoglobins, EPO-secreting tumors), where EPO is high or appropriately elevated.

Essential thrombocythemia features sustained thrombocytosis from megakaryocytic lineage drive (JAK2, CALR, or MPL mutations common). Primary myelofibrosis shows megakaryocytic proliferation, cytokine-driven marrow fibrosis, leukoerythroblastic smear with teardrop cells, and extramedullary hematopoiesis/splenomegaly. Shared teaching point: MPN mutations activate cytokine receptor signaling pathways (JAK–STAT axis), explaining lineage overproduction and the conceptual utility of JAK inhibition.

Integrating Leukocyte Neoplasm Questions

Approach vignettes by age and tempo (childhood ALL vs adult CLL/AML), presence or absence of blasts and marrow failure, lineage clues (Auer rods, TdT, basophilia), defining molecular lesions (BCR–ABL1, PML–RARA, JAK2, MYC, BCL2), and whether the process is a sparse RS-cell lymphoma versus a sheet-like NHL or a plasma-cell CRAB syndrome. Avoid relying on memorized fake staging cutoffs; CBSE rewards the cellular and molecular mechanism that produces the laboratory and clinical pattern.